#153996

RAP as an LRP1 antagonist

Cat. #153996

RAP as an LRP1 antagonist

Cat. #: 153996

Availability: Please enquire for quantities and pricing

Application: inhibition of LRP1 function

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Dudley K. Strickland

Institute: University of Maryland

Tool Details
Handling
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: RAP as an LRP1 antagonist
  • Alternate name: receptor-associated protein
  • Primary target: lipoprotein receptor-related protein 1
  • Description: LRP1 is an endocytic receptor that interacts with several ligands including alpha 2-macroglobulin. Functionally, the receptor mediates cellular signalling with implications in Alzheimer's disease. This receptor is expressed in brain, liver, and lung and localized to the cytoplasm and nucleus. Expression of LRP1 requires RAP, a molecular chaperone of LRP1.
  • Application: inhibition of LRP1 function
  • Additional notes: This RAP molecule was engineered to resist pH and heat-induced denaturation via the addition of a disulfide bond within the D3 domain and elimination of key histidine residues. This stable RAP molecule does not disassociate from LRP1 under acidic conditions and thus functions as a potent LRP1 antagonist both in-vitro and in-vivo.

Handling

  • Shipping conditions: Dry Ice

Target Details

  • Primary target: lipoprotein receptor-related protein 1

Application Details

  • Application: inhibition of LRP1 function

References

  • Prasad et al. 2015. J Biol Chem. 290(28):17262-8. PMID: 26013822.
  • Generation of a Potent Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Antagonist by Engineering a Stable Form of the Receptor-associated Protein (RAP) D3 Domain.